Brief: Beam Therapeutics Enrolls First Patient In Beacon Clinical Trial For The Treatment Of Sickle Cell Disease
14/11/2022 11:51
Nov 14 (Reuters) - Beam Therapeutics Inc BEAM.O :
* BEAM THERAPEUTICS ENROLLS FIRST PATIENT IN BEACON CLINICAL
TRIAL
OF BEAM-101 BASE EDITING THERAPY CANDIDATE FOR THE TREATMENT OF
SICKLE CELL DISEASE
Source text for Eikon: ID:nGNX9czbLp
Further company coverage: BEAM.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Beam Therapeutics
See all newsBeam Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Beam Therapeutics Q1 net loss narrows beating analyst estimates
U.S. STOCKS ON THE MOVE-ADMA Biologics, Nanobiotix, DraftKings
U.S. STOCKS ON THE MOVE-BWX, Generac, Cintas
U.S. STOCKS ON THE MOVE-Arm, On Holding, Sarepta